KeraVet® Bio, Inc., announces completion of a clinical study showing pet parents overwhelmingly prefer KeraVet Gel to a cone

KeraVet Bio, Inc., announced today that it has completed a controlled clinical study that shows that pet parents overwhelmingly prefer using KeraVet Gel to an Elizabethan collar (otherwise known as the cone or E-collar). This study is a follow-up to the randomized controlled clinical study KeraVet Bio completed that showed that the KeraVet Gel product significantly reduced licking behavior and improved healing outcomes (publication in review at the American Journal of Veterinary Research).

First Patient Dosed in Phase 2 Clinical Study of Palatin’s Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that patient dosing has started for the clinical study entitled: BMT-801: A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Study Investigating the Safety, Tolerability, and Effectiveness of the Co-Administration of Bremelanotide with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity (ClinicalTrials.gov Identifier: NCT06565611).

University of Miami serving as pilot study site for new, rapid coronavirus breathalyzer test

By participating in a short clinical research study that begins this week, the University of Miami became the first college testing site for a quick, easy, and cost-effective Israeli-produced COVID-19 Breath Analyzer that could revolutionize coronavirus testing if approved by the U.S. Food and Drug Administration (FDA).